Salute e Benessere

Santhera shares updates on commercial rollout of AGAMREE®

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from National Health Service (NHS) England is now available for AGAMREE for the treatment of DMD, enabling prescribing in England to commence. This follows positive NICE (National Institute for Health and Care Excellence) final guidance for AGAMREE announced onJanuary 16, 2025and...
Nasdaq GlobeNewswire
16/04/2025

Higher cantonal composition authority approved the amendments to the terms of…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority ( obere kantonale Nachlassbehörde ) (the Court) in relation to its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, which matured on January 17, 2025, was held yesterday and that the Court...
Nasdaq GlobeNewswire
16/04/2025

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year…

Total sales growth of 11.6% at CER 1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib regulatory submission to EMA 2for pediatric low-grade glioma. Confirmation of full-year 2025 financial guidance.PARIS, FRANCE, 16 April 2025 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025. Q1 2025% change...
Nasdaq GlobeNewswire
16/04/2025

TICA TESFU-205 Integrated Evaporative Cooling Chiller Wins Prestigious Red Dot…

Design & Sustainability in HarmonyThe chiller's smart, integrated control system, built on TICA's decades of technical expertise, enables seamless operation across diverse environments, from precision manufacturing facilities to comfort-focused commercial spaces. Its modular architecture supports TICA's end-to-end service model, ensuring rapid pre-sale customization, hassle-free installation, and lifelong maintenance—all while maintaining industry-leading performance and reliability…
PR Newswire
16/04/2025

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]. This is consistent with the positive efficacy signal generated in the IPAX-1 study in patients at first recurrence, with only one prior resection and treatment with standard chemoradiotherapy. IPAX-1 reported a…
PR Newswire
16/04/2025

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early…

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4 * ) non-carriers or heterozygotes with confirmed amyloid pathology Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early ADTOKYO and CAMBRIDGE, Mass., April15,...
Nasdaq GlobeNewswire
16/04/2025

Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's…

Takeda Pharmaceutical's ENTYVIO (vedolizumab) Overview Takeda Pharmaceutical's ENTYVIO (vedolizumab) Overview Vedolizumab is a biologic medication approved for both intravenous (IV) and subcutaneous (SC) use, with regulatory approvals varying by region. The SC formulation is authorized for use inthe United States, European Union, and over 50 other countries, while the IV formulation has received approval in more than 70 countries, including the US and the EU. Collectively, vedolizumab...
PR Newswire
15/04/2025

Inventiva announces filing of its 2024 Universal Registration Document and 2024…

Daix (France), New York City (New York, United States), April 15, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31,...
Nasdaq GlobeNewswire
15/04/2025

UK Pilot launched to detect early signs of dementia & improve brain health

"Many people avoid getting screened for dementia," says Jonathan Hanbury, CEO @Ness, "which means we only detect a small portion of those who are affected," he added. Waitlists in the UK to see a dementia specialist can be as long as 18 months, and there is little consistency in how the disease is monitored from that point onwards. "Many people avoid getting screened for dementia, " saysJonathan Hanbury, CEO @Ness, " which means we only detect a small portion…
PR Newswire
15/04/2025

EssilorLuxottica: Disclosure of transactions in own shares

Disclosure of transactions in own shares Paris, France (April 15, 2025 - 6:00 pm)– In accordance with the authorization granted by the Annual Shareholders' Meeting on April 30, 2024, EssilorLuxottica declares that from April 8, 2025, to April 14, 2025, inclusive, the following share buybacks were carried out: Name of the issuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)...
Nasdaq GlobeNewswire
15/04/2025

Virbac: In the first quarter of 2025, revenue recorded solid growth of +4.9% at…

In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope KEY FIGURES Revenue1 stquarter 2025 € 375.2MGrowth at constant exchange rates and scope 1+4.9%of which companion animals+5.6% farm animals +4.2%Growth at constantexchange rates +9.5% Overallchange +8.5%1 growth at constant exchange rates and scope corresponds to organic growth of sales,...
Nasdaq GlobeNewswire
15/04/2025

Nature's Best Experts Reveal the Top 5 Nutrients Backed by Science to Ease…

Nutrition plays a key role in mental well-being, with some regulating stress responses. Nutrition plays a key role in mental well-being, with some regulating stress responses. Nature's Best, one of the UK's leading nutritional supplement suppliers, shares five nutrients that may ease stress. Pauline Peh, Brand Lead of Nature's Best, said, "This research reinforces how crucial good nutrition is in managing stress. We often think stress is only tackled through exercise and self-care...
PR Newswire
15/04/2025

Eko Health Broadens Global Reach with UK Launch of AI-Powered Stethoscope…

This expansion builds on Eko's international momentum and collaborations with UK institutions, including Imperial College London, where Eko's technology supports earlier detection of heart disease in frontline care. This expansion builds on Eko's international momentum and collaborations with UK institutions, including Imperial College London , where Eko's technology supports earlier detection of heart disease in frontline care. "Bringing Eko's AI-powered technology directly to UK...
PR Newswire
15/04/2025

MAXIMA GRUPĖ amended credit agreements and increased financing by 29 mEUR back…

Financing is provided for the Company's general business needs for a new period of 5 (five) years and contains new flexible repayment schedule with close to 1/3 balloon repayment at maturity. Funds are expected to be used for the investments into expansion, reconstruction and operational efficiency. Financing agreements remain fully unsecured. Additional information MAXIMA GRUPĖ, UAB manages retail chains MAXIMA (in the Baltic countries), STOKROTKA (in Poland), T MARKET (in Bulgaria),...
Nasdaq GlobeNewswire
15/04/2025

US Ultrasound Market worth US$3.82 billion by 2030 with 7.6% CAGR |…

Browse in-depth TOC on "US Ultrasound Market" Browse in-depth TOC on "US Ultrasound Market" 400 - Tables45 - Figures By Based on segment,In the US, the ultrasound market is classified based on display into colour ultrasound and black & white ultrasound. In 2025, the colour ultrasound segment accounted for the largest share of the display segment. The high demand for colour ultrasound is attributed to being the most importantly used display in diagnosis cases related to...
PR Newswire
15/04/2025

Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals…

Collaboration will support access of an innovative treatment developed for numerous aggressive cancers heavily influenced by metabolic pathways Er-Kim Pharmaceuticals, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, today announced it has signed a distribution agreement withPolaris Pharmaceuticalsto commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region. Pegargiminase is an...
Nasdaq GlobeNewswire
15/04/2025

Macrium Partners with Sysmex America to Reduce Medical Testing Downtime and…

Addressing Critical Healthcare Challenges Addressing Critical Healthcare Challenges In healthcare settings, equipment downtime isn't just an inconvenience - it's a barrier to timely diagnosis and treatment. Sysmex America recognized this challenge and sought a solution that could minimize disruption while maintaining security standards. "The key objective is to reduce downtime as much as possible because any downtime has a negative impact on patient care which ultimately has a delay in...
PR Newswire
15/04/2025

Innocan Pharma Announces Closing of Private Placement

Each Unit is comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $0.25 for a period of four (4) years from the date of issuance. Each Unit is comprised of one common share of the Company (a " Common Share ") and one common share purchase warrant of the Company (a " Warrant "). Each…
PR Newswire
15/04/2025

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6…

Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast's interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference call. The webcast of the conference call will be available during and after the event...
Nasdaq GlobeNewswire
15/04/2025

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutionsSchlieren (Zurich), Switzerland, April 15, 2025– Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today.The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2024 and took note of the Reports of the Auditors. Shareholders granted discharge to the...
Nasdaq GlobeNewswire
15/04/2025

hellocare.ai Raises $47M to Accelerate AI-Assisted Virtual Care and Transform…

Already deployed across 70+ health systems, the investment fuels a period of hyper-growth for hellocare.ai, as demand accelerates for its unified virtual care platform. The platform that enables hospitals to deliver AI-assisted Virtual Nursing, Virtual Sitting, Virtual Consultation, Ambient Documentation, Digital Whiteboards, Patient Engagement, and Hospital-at-Home—all through one deeply integrated, enterprise-ready solution. The advancement and convergence of artificial intelligence and…
PR Newswire
15/04/2025

Shareholders approve all resolutions proposed by Board of Directors at Annual…

All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmedDividend of CHF 0.60 per registered dividend-paying share approved, representing 24% of core net incomeBasel, April 15, 2025 –Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements...
Nasdaq GlobeNewswire
15/04/2025

Virology Specimen Collection Market Size, Development, Key Opportunity…

Know about the future of Virology Specimen Collection Market and what makes it a Booming industry according to following research report
DLR
15/04/2025

RevitaLash® Cosmetics Announces Road to $10 Million Goal in Support of Breast…

As part of its ongoing Eternally Pink® pledge,��RevitaLash Cosmetics continues its year-round mission by committing a portion of proceeds from every product sold to directly fund important research and make quality care accessible to more patients. Recent initiatives have included the funding of a potentially groundbreaking study of Triple-Negative Breast Cancer at the renowned Francis Crick Institute in London, and scalp cooling treatments to help prevent hair loss in chemotherapy patients at…
PR Newswire
15/04/2025
Altri  Comunicati